These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 16569389)

  • 1. Barrett's esophagus and its progression to adenocarcinoma.
    Maley CC; Rustgi AK
    J Natl Compr Canc Netw; 2006 Apr; 4(4):367-74. PubMed ID: 16569389
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dietary supplement use and risk of neoplastic progression in esophageal adenocarcinoma: a prospective study.
    Dong LM; Kristal AR; Peters U; Schenk JM; Sanchez CA; Rabinovitch PS; Blount PL; Odze RD; Ayub K; Reid BJ; Vaughan TL
    Nutr Cancer; 2008; 60(1):39-48. PubMed ID: 18444134
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Determination of risk for Barrett's esophagus and esophageal adenocarcinoma.
    Thrift AP
    Curr Opin Gastroenterol; 2016 Jul; 32(4):319-24. PubMed ID: 27276368
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mutagen sensitivity and neoplastic progression in patients with Barrett's esophagus: a prospective analysis.
    Chao DL; Maley CC; Wu X; Farrow DC; Galipeau PC; Sanchez CA; Paulson TG; Rabinovitch PS; Reid BJ; Spitz MR; Vaughan TL
    Cancer Epidemiol Biomarkers Prev; 2006 Oct; 15(10):1935-40. PubMed ID: 17035402
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening for Barrett's esophagus.
    Zakko L; Lutzke L; Wang KK
    Minerva Med; 2017 Feb; 108(1):28-42. PubMed ID: 27792223
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The combination of genetic instability and clonal expansion predicts progression to esophageal adenocarcinoma.
    Maley CC; Galipeau PC; Li X; Sanchez CA; Paulson TG; Blount PL; Reid BJ
    Cancer Res; 2004 Oct; 64(20):7629-33. PubMed ID: 15492292
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonsteroidal anti-inflammatory drugs and esophageal inflammation - Barrett's esophagus - adenocarcinoma sequence: a meta-analysis.
    Wang F; Lv ZS; Fu YK
    Dis Esophagus; 2011 Jul; 24(5):318-24. PubMed ID: 21166737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nonsteroidal anti-inflammatory drugs and statins have chemopreventative effects in patients with Barrett's esophagus.
    Kastelein F; Spaander MC; Biermann K; Steyerberg EW; Kuipers EJ; Bruno MJ;
    Gastroenterology; 2011 Dec; 141(6):2000-8; quiz e13-4. PubMed ID: 21878200
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Surveillance in Barrett's esophagus].
    Leblanc S; Pommaret E; Coriat R; Prat F
    Presse Med; 2011 May; 40(5):508-15. PubMed ID: 21450439
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSAIDs modulate CDKN2A, TP53, and DNA content risk for progression to esophageal adenocarcinoma.
    Galipeau PC; Li X; Blount PL; Maley CC; Sanchez CA; Odze RD; Ayub K; Rabinovitch PS; Vaughan TL; Reid BJ
    PLoS Med; 2007 Feb; 4(2):e67. PubMed ID: 17326708
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reflux control is important in the management of Barrett's Esophagus: results from a retrospective 1,830 patient cohort.
    Brown CS; Lapin B; Wang C; Goldstein JL; Linn JG; Denham W; Haggerty SP; Talamonti MS; Howington JA; Carbray J; Ujiki MB
    Surg Endosc; 2015 Dec; 29(12):3528-34. PubMed ID: 25676204
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chemoprevention of Barrett's Esophagus and Esophageal Adenocarcinoma.
    Bresalier RS
    Dig Dis Sci; 2018 Aug; 63(8):2155-2162. PubMed ID: 29948566
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Surveillance for Barrett's oesophagus: worthwhile?].
    Kastelein F; Kuipers EJ
    Ned Tijdschr Geneeskd; 2012; 156(49):A5497. PubMed ID: 23218039
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The development of dysplasia and adenocarcinoma during endoscopic surveillance of Barrett's esophagus.
    Katz D; Rothstein R; Schned A; Dunn J; Seaver K; Antonioli D
    Am J Gastroenterol; 1998 Apr; 93(4):536-41. PubMed ID: 9576444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemoprevention of adenocarcinoma associated with Barrett's esophagus: potential options.
    Neumann H; Mönkemüller K; Vieth M; Malfertheiner P
    Dig Dis; 2009; 27(1):18-23. PubMed ID: 19439956
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ablative therapies for Barrett's esophagus.
    Garman KS; Shaheen NJ
    Curr Gastroenterol Rep; 2011 Jun; 13(3):226-39. PubMed ID: 21373836
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Risk factors, DNA damage, and disease progression in Barrett's esophagus.
    Olliver JR; Hardie LJ; Gong Y; Dexter S; Chalmers D; Harris KM; Wild CP
    Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):620-5. PubMed ID: 15767340
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predictors of Progression to High-Grade Dysplasia or Adenocarcinoma in Barrett's Esophagus.
    Whitson MJ; Falk GW
    Gastroenterol Clin North Am; 2015 Jun; 44(2):299-315. PubMed ID: 26021196
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The columnar-lined (Barrett's) esophagus. Can progression to cancer be prevented?
    Stollman N
    Postgrad Med; 2000 Jun; 107(7):59-65; quiz 216. PubMed ID: 10887445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multistage carcinogenesis in Barrett's esophagus.
    Maley CC
    Cancer Lett; 2007 Jan; 245(1-2):22-32. PubMed ID: 16713672
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.